Fecal Microbiota Transplantation Capsules with Targeted Colonic Versus Gastric Delivery in Recurrent Clostridium difficile Infection: A Comparative Cohort Analysis of High and Lose Dose
Background Fecal microbiota transplantation (FMT) is an effective therapy for recurrent Clostridium. difficile infection (rCDI). FMT capsules have emerged, and it is unknown if delivery location and dose impact efficacy. Methods We compared two cohorts of patients receiving two capsule formulations:...
Gespeichert in:
| Veröffentlicht in: | Digestive diseases and sciences 2019-06, Vol.64 (6), p.1672-1678 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1678 |
|---|---|
| container_issue | 6 |
| container_start_page | 1672 |
| container_title | Digestive diseases and sciences |
| container_volume | 64 |
| creator | Allegretti, Jessica R. Fischer, Monika Sagi, Sashidhar V. Bohm, Matthew E. Fadda, Hala M. Ranmal, Sejal R. Budree, Shrish Basit, Abdul W. Glettig, Dean L. de la Serna, Eva L. Gentile, Amanda Gerardin, Ylaine Timberlake, Sonia Sadovsky, Rotem Smith, Mark Kassam, Zain |
| description | Background
Fecal microbiota transplantation (FMT) is an effective therapy for recurrent
Clostridium. difficile
infection (rCDI). FMT capsules have emerged, and it is unknown if delivery location and dose impact efficacy.
Methods
We compared two cohorts of patients receiving two capsule formulations: gastric release (FMTgr) and targeted colonic release (FMTcr) at two different sites. Cohort A received FMTgr at (1)
high dose
: 60 capsules and
low dose
: 30 capsules. Patients in Cohort B received FMTcr at (1)
high dose
: 30 capsules (2)
low dose
: 10 capsules. Clinical cure rates and adverse events were monitored through week 8. Paired t-tests were used to compare diversity pre- and post-FMT.
Results
51 rCDI patients were enrolled. Cohort A contained
n
= 20 and Cohort B contained
n
= 31. Overall cure at week 8 for FMTgr was 75% (15/20) compared to 80.6% for FMTcr, (25/31),
p
= 0.63. Both formulations were safe with no serious adverse events. FMTcr was superior at increasing gut microbial diversity.
Discussion
To our knowledge, this is the first study to compare targeted delivery of FMT capsules. While both capsules were safe and efficacious, microbial engraftment patterns were superior in FMTcr. |
| doi_str_mv | 10.1007/s10620-018-5396-6 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2179233132</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A712937119</galeid><sourcerecordid>A712937119</sourcerecordid><originalsourceid>FETCH-LOGICAL-c481t-1d72db17f56b76d9bc297da3b1a1768944fc616519f5966316af15a33882bf423</originalsourceid><addsrcrecordid>eNp1kt2K1DAUx4so7jj6AN5IcG-86ZqTtEnr3TDrfsCIIKO3JU1PZrK0yZi0K_Novp0psyqKEkhOyO985p9lL4FeAKXybQQqGM0pVHnJa5GLR9kCSslzVorqcbagIJINIM6yZzHeUUprCeJpdsZpCXVVyEX2_Qq16skHq4NvrR8V2Qbl4qFXblSj9Y6s1SFOPUbyzY57slVhhyN2ZO1776wmXzDEKZJrFceQrpfY23sMR2Id-YR6CgHdSNa9n587Ow2ks8ZYbXskt86gnnO8I6sUbziokFLeY7L3Poxk5VR_jDYSb8iN3e2Jch3Z-IjkMm3PsydG9RFfPJzL7PPV--36Jt98vL5drza5LioYc-gk61qQphStFF3dalbLTvEWFEhR1UVhtACR5mHKWggOQhkoFedVxVpTML7M3pziHoL_OmEcm8FGjX2aEPopNgxkzTgHPqOv_0Lv_BRSFzNVcMZESrDMzk_QTvXYWGf8GJSeYzYrCazmEqBO1MU_qLQ6HKz2Dk2a4J8OcHJIHxljQNMcgh1UODZAm1ktzUktTVJLM6ulmUt59VDv1A7Y_fL4KY8EsBMQ05PbYfjd0P-j_gB9p8qY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>214322666</pqid></control><display><type>article</type><title>Fecal Microbiota Transplantation Capsules with Targeted Colonic Versus Gastric Delivery in Recurrent Clostridium difficile Infection: A Comparative Cohort Analysis of High and Lose Dose</title><source>MEDLINE</source><source>SpringerLink</source><creator>Allegretti, Jessica R. ; Fischer, Monika ; Sagi, Sashidhar V. ; Bohm, Matthew E. ; Fadda, Hala M. ; Ranmal, Sejal R. ; Budree, Shrish ; Basit, Abdul W. ; Glettig, Dean L. ; de la Serna, Eva L. ; Gentile, Amanda ; Gerardin, Ylaine ; Timberlake, Sonia ; Sadovsky, Rotem ; Smith, Mark ; Kassam, Zain</creator><creatorcontrib>Allegretti, Jessica R. ; Fischer, Monika ; Sagi, Sashidhar V. ; Bohm, Matthew E. ; Fadda, Hala M. ; Ranmal, Sejal R. ; Budree, Shrish ; Basit, Abdul W. ; Glettig, Dean L. ; de la Serna, Eva L. ; Gentile, Amanda ; Gerardin, Ylaine ; Timberlake, Sonia ; Sadovsky, Rotem ; Smith, Mark ; Kassam, Zain</creatorcontrib><description>Background
Fecal microbiota transplantation (FMT) is an effective therapy for recurrent
Clostridium. difficile
infection (rCDI). FMT capsules have emerged, and it is unknown if delivery location and dose impact efficacy.
Methods
We compared two cohorts of patients receiving two capsule formulations: gastric release (FMTgr) and targeted colonic release (FMTcr) at two different sites. Cohort A received FMTgr at (1)
high dose
: 60 capsules and
low dose
: 30 capsules. Patients in Cohort B received FMTcr at (1)
high dose
: 30 capsules (2)
low dose
: 10 capsules. Clinical cure rates and adverse events were monitored through week 8. Paired t-tests were used to compare diversity pre- and post-FMT.
Results
51 rCDI patients were enrolled. Cohort A contained
n
= 20 and Cohort B contained
n
= 31. Overall cure at week 8 for FMTgr was 75% (15/20) compared to 80.6% for FMTcr, (25/31),
p
= 0.63. Both formulations were safe with no serious adverse events. FMTcr was superior at increasing gut microbial diversity.
Discussion
To our knowledge, this is the first study to compare targeted delivery of FMT capsules. While both capsules were safe and efficacious, microbial engraftment patterns were superior in FMTcr.</description><identifier>ISSN: 0163-2116</identifier><identifier>EISSN: 1573-2568</identifier><identifier>DOI: 10.1007/s10620-018-5396-6</identifier><identifier>PMID: 30519847</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Analysis ; Biochemistry ; Capsules ; Care and treatment ; Clostridium Infections - diagnosis ; Clostridium Infections - microbiology ; Clostridium Infections - therapy ; Cohort analysis ; Colon - microbiology ; Diseases ; Fecal Microbiota Transplantation - adverse effects ; Fecal Microbiota Transplantation - instrumentation ; Female ; Fidaxomicin ; Gastroenterology ; Gastrointestinal Microbiome ; Health aspects ; Hepatology ; Humans ; Hydrogen-Ion Concentration ; Infection ; Male ; Medicine ; Medicine & Public Health ; Metronidazole ; Microbiota ; Microbiota (Symbiotic organisms) ; Middle Aged ; Oncology ; Original Article ; Relapse ; Remission Induction ; Stomach - microbiology ; Time Factors ; Transplant Surgery ; Treatment Outcome ; Young Adult</subject><ispartof>Digestive diseases and sciences, 2019-06, Vol.64 (6), p.1672-1678</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2018</rights><rights>COPYRIGHT 2019 Springer</rights><rights>Digestive Diseases and Sciences is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c481t-1d72db17f56b76d9bc297da3b1a1768944fc616519f5966316af15a33882bf423</citedby><cites>FETCH-LOGICAL-c481t-1d72db17f56b76d9bc297da3b1a1768944fc616519f5966316af15a33882bf423</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10620-018-5396-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10620-018-5396-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>315,781,785,27926,27927,41490,42559,51321</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30519847$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Allegretti, Jessica R.</creatorcontrib><creatorcontrib>Fischer, Monika</creatorcontrib><creatorcontrib>Sagi, Sashidhar V.</creatorcontrib><creatorcontrib>Bohm, Matthew E.</creatorcontrib><creatorcontrib>Fadda, Hala M.</creatorcontrib><creatorcontrib>Ranmal, Sejal R.</creatorcontrib><creatorcontrib>Budree, Shrish</creatorcontrib><creatorcontrib>Basit, Abdul W.</creatorcontrib><creatorcontrib>Glettig, Dean L.</creatorcontrib><creatorcontrib>de la Serna, Eva L.</creatorcontrib><creatorcontrib>Gentile, Amanda</creatorcontrib><creatorcontrib>Gerardin, Ylaine</creatorcontrib><creatorcontrib>Timberlake, Sonia</creatorcontrib><creatorcontrib>Sadovsky, Rotem</creatorcontrib><creatorcontrib>Smith, Mark</creatorcontrib><creatorcontrib>Kassam, Zain</creatorcontrib><title>Fecal Microbiota Transplantation Capsules with Targeted Colonic Versus Gastric Delivery in Recurrent Clostridium difficile Infection: A Comparative Cohort Analysis of High and Lose Dose</title><title>Digestive diseases and sciences</title><addtitle>Dig Dis Sci</addtitle><addtitle>Dig Dis Sci</addtitle><description>Background
Fecal microbiota transplantation (FMT) is an effective therapy for recurrent
Clostridium. difficile
infection (rCDI). FMT capsules have emerged, and it is unknown if delivery location and dose impact efficacy.
Methods
We compared two cohorts of patients receiving two capsule formulations: gastric release (FMTgr) and targeted colonic release (FMTcr) at two different sites. Cohort A received FMTgr at (1)
high dose
: 60 capsules and
low dose
: 30 capsules. Patients in Cohort B received FMTcr at (1)
high dose
: 30 capsules (2)
low dose
: 10 capsules. Clinical cure rates and adverse events were monitored through week 8. Paired t-tests were used to compare diversity pre- and post-FMT.
Results
51 rCDI patients were enrolled. Cohort A contained
n
= 20 and Cohort B contained
n
= 31. Overall cure at week 8 for FMTgr was 75% (15/20) compared to 80.6% for FMTcr, (25/31),
p
= 0.63. Both formulations were safe with no serious adverse events. FMTcr was superior at increasing gut microbial diversity.
Discussion
To our knowledge, this is the first study to compare targeted delivery of FMT capsules. While both capsules were safe and efficacious, microbial engraftment patterns were superior in FMTcr.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Analysis</subject><subject>Biochemistry</subject><subject>Capsules</subject><subject>Care and treatment</subject><subject>Clostridium Infections - diagnosis</subject><subject>Clostridium Infections - microbiology</subject><subject>Clostridium Infections - therapy</subject><subject>Cohort analysis</subject><subject>Colon - microbiology</subject><subject>Diseases</subject><subject>Fecal Microbiota Transplantation - adverse effects</subject><subject>Fecal Microbiota Transplantation - instrumentation</subject><subject>Female</subject><subject>Fidaxomicin</subject><subject>Gastroenterology</subject><subject>Gastrointestinal Microbiome</subject><subject>Health aspects</subject><subject>Hepatology</subject><subject>Humans</subject><subject>Hydrogen-Ion Concentration</subject><subject>Infection</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metronidazole</subject><subject>Microbiota</subject><subject>Microbiota (Symbiotic organisms)</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Relapse</subject><subject>Remission Induction</subject><subject>Stomach - microbiology</subject><subject>Time Factors</subject><subject>Transplant Surgery</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0163-2116</issn><issn>1573-2568</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kt2K1DAUx4so7jj6AN5IcG-86ZqTtEnr3TDrfsCIIKO3JU1PZrK0yZi0K_Novp0psyqKEkhOyO985p9lL4FeAKXybQQqGM0pVHnJa5GLR9kCSslzVorqcbagIJINIM6yZzHeUUprCeJpdsZpCXVVyEX2_Qq16skHq4NvrR8V2Qbl4qFXblSj9Y6s1SFOPUbyzY57slVhhyN2ZO1776wmXzDEKZJrFceQrpfY23sMR2Id-YR6CgHdSNa9n587Ow2ks8ZYbXskt86gnnO8I6sUbziokFLeY7L3Poxk5VR_jDYSb8iN3e2Jch3Z-IjkMm3PsydG9RFfPJzL7PPV--36Jt98vL5drza5LioYc-gk61qQphStFF3dalbLTvEWFEhR1UVhtACR5mHKWggOQhkoFedVxVpTML7M3pziHoL_OmEcm8FGjX2aEPopNgxkzTgHPqOv_0Lv_BRSFzNVcMZESrDMzk_QTvXYWGf8GJSeYzYrCazmEqBO1MU_qLQ6HKz2Dk2a4J8OcHJIHxljQNMcgh1UODZAm1ktzUktTVJLM6ulmUt59VDv1A7Y_fL4KY8EsBMQ05PbYfjd0P-j_gB9p8qY</recordid><startdate>20190615</startdate><enddate>20190615</enddate><creator>Allegretti, Jessica R.</creator><creator>Fischer, Monika</creator><creator>Sagi, Sashidhar V.</creator><creator>Bohm, Matthew E.</creator><creator>Fadda, Hala M.</creator><creator>Ranmal, Sejal R.</creator><creator>Budree, Shrish</creator><creator>Basit, Abdul W.</creator><creator>Glettig, Dean L.</creator><creator>de la Serna, Eva L.</creator><creator>Gentile, Amanda</creator><creator>Gerardin, Ylaine</creator><creator>Timberlake, Sonia</creator><creator>Sadovsky, Rotem</creator><creator>Smith, Mark</creator><creator>Kassam, Zain</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20190615</creationdate><title>Fecal Microbiota Transplantation Capsules with Targeted Colonic Versus Gastric Delivery in Recurrent Clostridium difficile Infection: A Comparative Cohort Analysis of High and Lose Dose</title><author>Allegretti, Jessica R. ; Fischer, Monika ; Sagi, Sashidhar V. ; Bohm, Matthew E. ; Fadda, Hala M. ; Ranmal, Sejal R. ; Budree, Shrish ; Basit, Abdul W. ; Glettig, Dean L. ; de la Serna, Eva L. ; Gentile, Amanda ; Gerardin, Ylaine ; Timberlake, Sonia ; Sadovsky, Rotem ; Smith, Mark ; Kassam, Zain</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c481t-1d72db17f56b76d9bc297da3b1a1768944fc616519f5966316af15a33882bf423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Analysis</topic><topic>Biochemistry</topic><topic>Capsules</topic><topic>Care and treatment</topic><topic>Clostridium Infections - diagnosis</topic><topic>Clostridium Infections - microbiology</topic><topic>Clostridium Infections - therapy</topic><topic>Cohort analysis</topic><topic>Colon - microbiology</topic><topic>Diseases</topic><topic>Fecal Microbiota Transplantation - adverse effects</topic><topic>Fecal Microbiota Transplantation - instrumentation</topic><topic>Female</topic><topic>Fidaxomicin</topic><topic>Gastroenterology</topic><topic>Gastrointestinal Microbiome</topic><topic>Health aspects</topic><topic>Hepatology</topic><topic>Humans</topic><topic>Hydrogen-Ion Concentration</topic><topic>Infection</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metronidazole</topic><topic>Microbiota</topic><topic>Microbiota (Symbiotic organisms)</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Relapse</topic><topic>Remission Induction</topic><topic>Stomach - microbiology</topic><topic>Time Factors</topic><topic>Transplant Surgery</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Allegretti, Jessica R.</creatorcontrib><creatorcontrib>Fischer, Monika</creatorcontrib><creatorcontrib>Sagi, Sashidhar V.</creatorcontrib><creatorcontrib>Bohm, Matthew E.</creatorcontrib><creatorcontrib>Fadda, Hala M.</creatorcontrib><creatorcontrib>Ranmal, Sejal R.</creatorcontrib><creatorcontrib>Budree, Shrish</creatorcontrib><creatorcontrib>Basit, Abdul W.</creatorcontrib><creatorcontrib>Glettig, Dean L.</creatorcontrib><creatorcontrib>de la Serna, Eva L.</creatorcontrib><creatorcontrib>Gentile, Amanda</creatorcontrib><creatorcontrib>Gerardin, Ylaine</creatorcontrib><creatorcontrib>Timberlake, Sonia</creatorcontrib><creatorcontrib>Sadovsky, Rotem</creatorcontrib><creatorcontrib>Smith, Mark</creatorcontrib><creatorcontrib>Kassam, Zain</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health & Medical Collection (ProQuest Medical & Health Databases)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Digestive diseases and sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Allegretti, Jessica R.</au><au>Fischer, Monika</au><au>Sagi, Sashidhar V.</au><au>Bohm, Matthew E.</au><au>Fadda, Hala M.</au><au>Ranmal, Sejal R.</au><au>Budree, Shrish</au><au>Basit, Abdul W.</au><au>Glettig, Dean L.</au><au>de la Serna, Eva L.</au><au>Gentile, Amanda</au><au>Gerardin, Ylaine</au><au>Timberlake, Sonia</au><au>Sadovsky, Rotem</au><au>Smith, Mark</au><au>Kassam, Zain</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fecal Microbiota Transplantation Capsules with Targeted Colonic Versus Gastric Delivery in Recurrent Clostridium difficile Infection: A Comparative Cohort Analysis of High and Lose Dose</atitle><jtitle>Digestive diseases and sciences</jtitle><stitle>Dig Dis Sci</stitle><addtitle>Dig Dis Sci</addtitle><date>2019-06-15</date><risdate>2019</risdate><volume>64</volume><issue>6</issue><spage>1672</spage><epage>1678</epage><pages>1672-1678</pages><issn>0163-2116</issn><eissn>1573-2568</eissn><abstract>Background
Fecal microbiota transplantation (FMT) is an effective therapy for recurrent
Clostridium. difficile
infection (rCDI). FMT capsules have emerged, and it is unknown if delivery location and dose impact efficacy.
Methods
We compared two cohorts of patients receiving two capsule formulations: gastric release (FMTgr) and targeted colonic release (FMTcr) at two different sites. Cohort A received FMTgr at (1)
high dose
: 60 capsules and
low dose
: 30 capsules. Patients in Cohort B received FMTcr at (1)
high dose
: 30 capsules (2)
low dose
: 10 capsules. Clinical cure rates and adverse events were monitored through week 8. Paired t-tests were used to compare diversity pre- and post-FMT.
Results
51 rCDI patients were enrolled. Cohort A contained
n
= 20 and Cohort B contained
n
= 31. Overall cure at week 8 for FMTgr was 75% (15/20) compared to 80.6% for FMTcr, (25/31),
p
= 0.63. Both formulations were safe with no serious adverse events. FMTcr was superior at increasing gut microbial diversity.
Discussion
To our knowledge, this is the first study to compare targeted delivery of FMT capsules. While both capsules were safe and efficacious, microbial engraftment patterns were superior in FMTcr.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>30519847</pmid><doi>10.1007/s10620-018-5396-6</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0163-2116 |
| ispartof | Digestive diseases and sciences, 2019-06, Vol.64 (6), p.1672-1678 |
| issn | 0163-2116 1573-2568 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2179233132 |
| source | MEDLINE; SpringerLink |
| subjects | Adult Aged Aged, 80 and over Analysis Biochemistry Capsules Care and treatment Clostridium Infections - diagnosis Clostridium Infections - microbiology Clostridium Infections - therapy Cohort analysis Colon - microbiology Diseases Fecal Microbiota Transplantation - adverse effects Fecal Microbiota Transplantation - instrumentation Female Fidaxomicin Gastroenterology Gastrointestinal Microbiome Health aspects Hepatology Humans Hydrogen-Ion Concentration Infection Male Medicine Medicine & Public Health Metronidazole Microbiota Microbiota (Symbiotic organisms) Middle Aged Oncology Original Article Relapse Remission Induction Stomach - microbiology Time Factors Transplant Surgery Treatment Outcome Young Adult |
| title | Fecal Microbiota Transplantation Capsules with Targeted Colonic Versus Gastric Delivery in Recurrent Clostridium difficile Infection: A Comparative Cohort Analysis of High and Lose Dose |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T19%3A00%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fecal%20Microbiota%20Transplantation%20Capsules%20with%20Targeted%20Colonic%20Versus%20Gastric%20Delivery%20in%20Recurrent%20Clostridium%20difficile%20Infection:%20A%20Comparative%20Cohort%20Analysis%20of%20High%20and%20Lose%20Dose&rft.jtitle=Digestive%20diseases%20and%20sciences&rft.au=Allegretti,%20Jessica%20R.&rft.date=2019-06-15&rft.volume=64&rft.issue=6&rft.spage=1672&rft.epage=1678&rft.pages=1672-1678&rft.issn=0163-2116&rft.eissn=1573-2568&rft_id=info:doi/10.1007/s10620-018-5396-6&rft_dat=%3Cgale_proqu%3EA712937119%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=214322666&rft_id=info:pmid/30519847&rft_galeid=A712937119&rfr_iscdi=true |